Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway

被引:95
作者
Yan, Jun
Yu, Cheng-Tai
Ozen, Mustafa
Ittmann, Nlichael
Tsai, Sophia Y.
Tsai, Ming-Jer
机构
[1] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[3] Baylor Coll Med, Program Dev, Houston, TX 77030 USA
[4] Baylor Coll Med, Baylor Prostate Canc Specialized Programs Res Exc, Houston, TX 77030 USA
关键词
D O I
10.1158/0008-5472.CAN-06-2442
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Steroid receptor coactivator (SRC)-3, also called amplified in breast cancer 1, is a member of the p160 nuclear receptor coactivator family involved in transcriptional regulation of target genes. SRC-3 is frequently amplified and/or overexpressed in hormone-sensitive and hormone-insensitive tumors. We reported previously that SRC-3 stimulated prostate cell growth in a hormone-independent manner through activation of AKT signaling pathway. However, the underlying mechanism remains undefined. Here, we! exploited the mifepristone-induced SRC-3 LNCaP prostate cancer cell line generated in our laboratory to identify SRC-3-regulated genes by oligonucleotide microarray analysis. We found that SRC-3 up-regulates the expression of multiple genes in the insulin-like growth factor (IGF)/AKT signaling pathway that are involved in cell proliferation and survival. In contrast, knockdown of SRC-3 in PC3 (androgen receptor negative) prostate cancer cells and MCF-7 breast cancer cells reduces their expression. Similarly, in prostate glands of SRC-3 null mice, expressions of these components in the IGF/AKT signal pathway are also reduced. Chromatin immunoprecipitation assay revealed that SRC-3 was directly recruited to the promoters of these genes, indicating that they are direct targets of SRC-3. Interestingly, we showed that recruitment of SRC-3 to two target promoters, IRS-2 and IGF-I, requires transcription factor activator protein-1 (AP-1). Taken together, our results clearly show that SRC-3 and AP-1 can coordinately regulate the transcription of multiple components in the IGF/AKT pathway to ensure ligand-independent cell proliferation and survival of cancer cells.
引用
收藏
页码:11039 / 11046
页数:8
相关论文
共 51 条
[21]   Direct control of cell cycle gene expression by proto-oncogene product ACTR, an its autoregulation underlies its transforming activity [J].
Louie, Maggie C. ;
Revenko, Alexey S. ;
Zou, June X. ;
Yao, Jennifer ;
Chen, Hong-Wu .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (10) :3810-3823
[22]   ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance [J].
Louie, MC ;
Zou, JX ;
Rabinovich, A ;
Chen, HW .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (12) :5157-5171
[23]   cFos is critical for MCF-7 breast cancer cell growth [J].
Lu, CH ;
Shen, Q ;
DuPre, E ;
Kim, H ;
Hilsenbeck, S ;
Brown, PH .
ONCOGENE, 2005, 24 (43) :6516-6524
[24]   Combinatorial control of gene expression by nuclear receptors and coregulators [J].
McKenna, NJ ;
O'Malley, BW .
CELL, 2002, 108 (04) :465-474
[25]   The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas [J].
Milde-Langosch, K ;
Röder, H ;
Andritzky, B ;
Aslan, B ;
Hemminger, G ;
Brinkmann, A ;
Bamberger, CM ;
Löning, T ;
Bamberger, AM .
BREAST CANCER RESEARCH AND TREATMENT, 2004, 86 (02) :139-152
[26]   Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines [J].
Nakatani, K ;
Thompson, DA ;
Barthel, A ;
Sakaue, H ;
Liu, W ;
Weigel, RJ ;
Roth, RA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (31) :21528-21532
[27]   The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells [J].
Oh, A ;
List, HJ ;
Reiter, R ;
Mani, A ;
Zhang, Y ;
Gehan, E ;
Wellstein, A ;
Riegel, AT .
CANCER RESEARCH, 2004, 64 (22) :8299-8308
[28]   Insulin-like growth factors and neoplasia [J].
Pollak, MN ;
Schernhammer, ES ;
Hankinson, SE .
NATURE REVIEWS CANCER, 2004, 4 (07) :505-518
[29]  
Polnaszek N, 2003, CANCER RES, V63, P5754
[30]  
Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.0.CO